Tenaya Therapeutics (NASDAQ:TNYA) Releases Quarterly Earnings Results

Tenaya Therapeutics (NASDAQ:TNYA) released its quarterly earnings results on Wednesday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.10) by $0.02, FiscalAI reports. The firm had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $0.80 million.

Tenaya Therapeutics Stock Up 2.7%

Shares of TNYA traded up $0.01 during trading hours on Wednesday, reaching $0.37. 1,602,720 shares of the company traded hands, compared to its average volume of 3,456,521. The stock has a market capitalization of $84.31 million, a P/E ratio of -0.70 and a beta of 2.88. The business has a fifty day moving average price of $0.56 and a 200-day moving average price of $0.71. Tenaya Therapeutics has a 12-month low of $0.35 and a 12-month high of $1.56.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the stock. Wall Street Zen raised shares of Tenaya Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, September 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tenaya Therapeutics in a research report on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $4.00.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc is a clinical-stage biotechnology company focused on developing therapies for genetic and other serious diseases of the heart. The company combines gene therapy, gene editing, cell therapy and small-molecule drug discovery technologies to target the underlying causes of cardiovascular disease rather than treating symptoms alone.

Tenaya’s pipeline has included TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed for PKP2-associated arrhythmogenic right ventricular cardiomyopathy.